Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

1. Dimopoulos, M.A.
2. Richardson, P.G.
3. Bahlis, N.J.
4. Grosicki, S.
5. Cavo, M.
6. Beksaç, M.
7. Legieć, W.
8. Liberati, A.M.
9. Goldschmidt, H.
10. Belch, A.
11. Magen, H.
12. Larocca, A.
13. Laubach, J.P.
14. Petrucci, M.T.
15. Reece, D.
16. White, D.
17. Mateos, M.-V.
18. Špička, I.
19. Lazaroiu, M.
20. Berdeja, J.
21. Kaufman, J.L.
22. Jou, Y.-M.
23. Ganetsky, A.
24. Popa McKiver, M.
25. Lonial, S.
26. Weisel, K.
27. Mostra tots els autors/es +